A new report that identifies specific risks and informational needs of certain ‘at-risk’ groups in Scotland has been published today by Scottish Drugs Forum
Bibliography: Interventions – Harm Reduction
Does it matter where you get medication for opioid use disorder? A comparison of three types of clinics
Do substance-related outcomes vary across different types of community clinics? (Recovery Research Institute)
Substance use disorder recovery – there’s an app for that… but who uses it and who benefits?
To begin to address this gap in the clinical literature, the authors conducted an analysis of Sober Grid, a popular substance use disorder (SUD) recovery smartphone application (Recovery Research Institute)
Managing drug and alcohol misuse at work
Our report, written with input from charities and experts in the space, examines the management and prevention of drug and alcohol misuse at work (CIPD)
Overdose Education and Naloxone Distribution Within Syringe Service Programs — United States, 2019
In 2019, among 263 SSPs responding to an online survey, 247 (94%) had implemented OEND. The number of persons who received naloxone per opioid overdose death and the number of naloxone doses distributed per opioid overdose death during the previous year varied by census division (CDC)
Access to take-home naloxone increased through paramedic supply
Ambulance paramedics are to supply to patients at risk of an opiate overdose take-home naloxone as part of a pilot scheme in Glasgow (SDF)
National Naloxone programme Scotland
This release by Public Health Scotland presents information on the number of take-home naloxone kits issued by the National Naloxone Programme in Scotlan
Physicians’ progress toward ending the nation’s drug overdose and death epidemic
The nation’s continuing increase in drug overdoses is fuelling the evolution of a more dangerous and complicated epidemic (AMA)
Scottish Drug Deaths Taskforce: One Year Report
This report details the work and achievements of the Drug Deaths Taskforce following its establishment in July 2019
Injecting equipment provision in Scotland
This release by Public Health Scotland presents information on the provision of injecting equipmen
Medicinal Use of Psilocybin: Reducing restrictions on research and treatment
The Adam Smith Institute, in conjunction with the Conservative Drug Policy Reform Group (CDPRG), has published a new report outlining the medical potential of psilocybin and the need to reduce restrictions on research and treatmen
A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report
This report describes the development of a national model of remote care to eliminate waiting lists and increase access to OAT in Ireland (BMC)
Summing it up: Building evidence to inform advocacy for harm reduction funding in Asia
Harm Reduction International developed tools for assessing national harm reduction investment and spending on drug law enforcement. This report presents the research findings generated by these tools in seven Asian countries. It provides insights on the state of harm reduction financing, informed by donor and government stakeholders, civil society and community representatives (HRI)
Saving Lives in the time of COVID-19
Case Study of Harm Reduction, Homelessness and Drug Use in Dublin, Ireland (LSE)
Key findings from the ‘Australians’ Drug Use: Adapting to Pandemic Threats’ (ADAPT) Study
The Australians’ Drug Use: Adapting to Pandemic Threats (ADAPT) Study is exploring the short and long-term impact of the COVID-19 pandemic on the experiences of Australians who use illicit drugs (NDARC)
Drugs, Prisons and ‘Unintended Consequences’ – Does drug interdiction drive drug-related harms?
The availability and use of drugs in prisons cannot be separated from wider drug policy. The criminalisation of drugs and the people who use or sell them fuels mass incarceration in many countries, and in doing so creates large profitable markets for drugs behind bars (Gdpo)
Impacts of COVID-19 and associated restrictions on people who use illicit stimulants in Australia
Preliminary findings from the Ecstasy and Related Drugs Reporting System 2020 (NDARC)
Original quantitative research – Setting the baseline
A description of cannabis poisonings at a Canadian pediatric hospital prior to the legalization of recreational cannabis (Public Health Agency of Canada)
Trends in awareness, uptake and deployment of naloxone among a sample of people who inject drugs in Australia
This bulletin describes the awareness of naloxone and the take-home naloxone program in Australia, both nationally and by jurisdiction. It also explores access, use and acceptance of naloxone, and examines demographic differences for these aspects (NDARC)
Adulterants, Contaminants and Co-occurring Substances in Drugs on the Illegal Market in Canada
Provides a snapshot of the contents of drugs on the illegal market in Canada using 2018–2019 data from drug seizures, drug checking services and a drug monitoring study. This bulletin is accompanied by a technical report featuring detailed research methods and data PDF (CCENDU )
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 19
- Next Page »
